As of Friday close, Recursion Pharmaceuticals Inc.’s (NASDAQ:RXRX) stock was up $0.02, moving up 0.20 percent to $12.40. The average number of shares traded per day over the past five days has been 3,720,320 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.72 fall in that time frame. In the last twenty days, the average volume was 12,840,055, while in the previous 50 days, it was 6,360,826.
Since last month, RXRX stock rose 88.16%. Shares of the company fell to $6.44 on 07/06/23, the lowest level in the past month. A 52-week high of $16.75 was reached on 07/19/23 after having rallying from a 52-week low of $4.54. Since the beginning of this year, RXRX’s stock price has risen by 60.83% or $4.69, and marked a new high 14 times. However, the stock has declined by -25.95% since its 52-week high.
RXRX stock investors should be aware that Recursion Pharmaceuticals Inc. (RXRX) stock had its last reported insider trading activity 3 days ago on Aug 02. Gibson Christopher, the Chief Executive Officer of the company, disposed of 65,015 shares for $13.04 on Aug 02. It resulted in a $847,712 divestment by the insider. Larson Tina Marriott sold 8,000 shares at an average price of $13.62 on Jul 27. The insider now owns 424,160 shares following the transaction. On Jul 26, Chief Business Officer Virani Shafique sold 20,000 shares at $14.41 apiece. The transaction was valued at $288,200.
Valuation Metrics
The stock’s beta is -0.12. Besides these, the trailing price-to-sales (P/S) ratio of 50.37, the price-to-book (PB) ratio of 5.54.
Financial Health
In the three months ended March 30, Recursion Pharmaceuticals Inc.’s quick ratio stood at 5.30, while its current ratio was 5.30, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is -13.50% percent. Based on annual data, RXRX earned -$8.43 million in gross profit and brought in $39.84 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -50.50%. Return on equity (ROE) for the past 12 months was -57.10%.
In Recursion Pharmaceuticals Inc.’s quarter-end financial report for March 30, it reported total debt of $1.18 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RXRX’s revenue rose 56.06% to $13.68 million during the quarter, while net income inched up to $12.13 million. While analysts expected Recursion Pharmaceuticals Inc. to report -$0.35 quarterly earnings, the actual figure was -$0.34 per share, beating the consensus estimate by 2.90%. During the quarter, the company generated -$66.14 million in EBITDA. The liabilities of Recursion Pharmaceuticals Inc. were 197.19 million at the end of its most recent quarter ended March 30, and its total debt was $53.05 million. The value of shareholders’ equity is $192.36 million.
Technical Picture
This quick technical analysis looks at Recursion Pharmaceuticals Inc.’s (RXRX) price momentum. With a historical volatility rate of 71.85%, the RSI 9-day stood at 47.06% on 04 August.
With respect to its five-day moving average, the current Recursion Pharmaceuticals Inc. price is down by -5.49% percent or -$0.72. At present, RXRX shares trade +80.76% above its 20-day simple moving average and +61.67% percent above its 100-day simple moving average. However, the stock is currently trading approximately +34.05% above its SMA50 and +19.12% above its SMA200.
Stochastic coefficient K was 18.64% and Stochastic coefficient D was 33.31%, while ATR was 1.35. Given the Stochastic reading of 9.01% for the 14-day period, the RSI (14) reading has been calculated as 52.52%. As of today, the MACD Oscillator reading stands at -0.71, while the 14-day reading stands at -1.23.
Analyst Ratings
Morgan Stanley launched its rating on Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) to an Equal-weight in a note to investors on May 22, 2023. Recursion Pharmaceuticals Inc. (RXRX) has been rated Overweight by analysts. According to 0 brokerage firms, RXRX is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Recursion Pharmaceuticals Inc. stock as buy, with 3 recommending it as overweight.
